NASDAQ: AIMD
Ainos Inc Stock

$2.98-0.16 (-5.1%)
Updated Jul 11, 2025
AIMD Price
$2.98
Fair Value Price
-$0.89
Market Cap
$12.38M
52 Week Low
$2.00
52 Week High
$5.00
P/E
-0.46x
P/B
0.94x
P/S
73.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$106.21k
Earnings
-$14.83M
Gross Margin
58.5%
Operating Margin
-13,262.17%
Profit Margin
-13,967.4%
Debt to Equity
1.01
Operating Cash Flow
-$6M
Beta
299.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

AIMD Overview

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine AIMD's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
AIMD
Ranked
Unranked of 104

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$11.93A
$228.03A
$30.28A
View Top Medical Device Stocks

Be the first to know about important AIMD news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AIMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AIMD ($2.98) is overvalued by 433.98% relative to our estimate of its Fair Value price of -$0.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AIMD ($2.98) is not significantly undervalued (433.98%) relative to our estimate of its Fair Value price of -$0.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AIMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AIMD due diligence checks available for Premium users.

Valuation

AIMD fair value

Fair Value of AIMD stock based on Discounted Cash Flow (DCF)

Price
$2.98
Fair Value
-$0.89
Undervalued by
433.98%
AIMD ($2.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AIMD ($2.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AIMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AIMD price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.46x
Industry
35.68x
Market
30.99x

AIMD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.94x
Industry
4.06x
AIMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AIMD's financial health

Profit margin

Revenue
$106.2k
Net Income
-$3.3M
Profit Margin
-3,094%
AIMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AIMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$26.4M
Liabilities
$13.2M
Debt to equity
1.01
AIMD's short-term assets ($3.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIMD's long-term liabilities ($11.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.2M
Investing
-$20.6k
Financing
$14.6k
AIMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AIMD vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
AIMD$12.38M-5.10%-0.46x0.94x
INBS$12.23M-3.28%-1.28x2.39x
DHAI$12.21M-4.09%N/A-0.32x
WOK$11.05M-1.69%-2.80x0.84x
PAVM$10.52M-0.50%0.09x0.23x

Ainos Stock FAQ

What is Ainos's quote symbol?

(NASDAQ: AIMD) Ainos trades on the NASDAQ under the ticker symbol AIMD. Ainos stock quotes can also be displayed as NASDAQ: AIMD.

If you're new to stock investing, here's how to buy Ainos stock.

What is the 52 week high and low for Ainos (NASDAQ: AIMD)?

(NASDAQ: AIMD) Ainos's 52-week high was $5.00, and its 52-week low was $2.00. It is currently -40.4% from its 52-week high and 49% from its 52-week low.

How much is Ainos stock worth today?

(NASDAQ: AIMD) Ainos currently has 4,152,845 outstanding shares. With Ainos stock trading at $2.98 per share, the total value of Ainos stock (market capitalization) is $12.38M.

Ainos stock was originally listed at a price of $0.18 in Jan 19, 2021. If you had invested in Ainos stock at $0.18, your return over the last 4 years would have been 1,519.57%, for an annualized return of 100.61% (not including any dividends or dividend reinvestments).

How much is Ainos's stock price per share?

(NASDAQ: AIMD) Ainos stock price per share is $2.98 today (as of Jul 11, 2025).

What is Ainos's Market Cap?

(NASDAQ: AIMD) Ainos's market cap is $12.38M, as of Jul 13, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ainos's market cap is calculated by multiplying AIMD's current stock price of $2.98 by AIMD's total outstanding shares of 4,152,845.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.